<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002633</url>
  </required_header>
  <id_info>
    <org_study_id>PR3</org_study_id>
    <secondary_id>CAN-NCIC-PR3</secondary_id>
    <secondary_id>ECOG-JPR03</secondary_id>
    <secondary_id>MRC-PR07</secondary_id>
    <secondary_id>SWOG-JPR3</secondary_id>
    <secondary_id>EU-99013</secondary_id>
    <secondary_id>NCI-T94-0110O</secondary_id>
    <secondary_id>ISRCTN24991896</secondary_id>
    <secondary_id>CDR0000064065</secondary_id>
    <nct_id>NCT00002633</nct_id>
  </id_info>
  <brief_title>Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may
      fight prostate cancer by reducing the production of androgens. Radiation therapy uses
      high-energy x-rays to damage tumor cells. It is not yet known whether hormone therapy plus
      surgery is more effective than hormone therapy plus radiation therapy for prostate cancer.

      PURPOSE: This randomized phase III trial is studying giving hormone therapy alone to see how
      well it works compared to giving hormone therapy together with bilateral orchiectomy or
      radiation therapy in treating patients with stage III or stage IV prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the overall survival, disease specific survival, and time to progression in
           patients with locally advanced adenocarcinoma of the prostate treated with total
           androgen suppression with or without pelvic irradiation.

        -  Compare the symptomatic control as measured by the rates of surgical interventions
           needed for control of local disease (e.g., transurethral resections, stent insertions,
           nephrostomies, and colostomies) in patients treated with these regimens.

        -  Compare the quality of life of patients treated with these regimens.

        -  Compare the sensitivity of the EORTC-QLQ-C30+3 and a trial-specific checklist (PR17)
           with the FACT-P questionnaire in measuring changes in quality of life of patients
           treated with these regimens.

      OUTLINE: This a randomized, multicenter study. Patients are stratified according to center,
      initial PSA level (less than 20 vs 20-50 vs greater than 50 ng/mL), method of node staging
      (clinical [no CT scan] vs radiological [CT scan negative] vs surgical), Gleason score (less
      than 8 vs 8-10), prior hormonal therapy (excluding orchiectomy) (yes vs no), and choice of
      hormonal therapy (bilateral orchiectomy with or without antiandrogen vs luteinizing
      hormone-releasing hormone [LHRH] with antiandrogen). Patients are randomized to 1 of 2
      treatment arms.

        -  Arm I: Patients receive antiandrogen therapy comprising oral flutamide every 8 hours,
           oral nilutamide every 8 hours for 1 month and then once daily, or oral bicalutamide once
           daily. Patients also choose to undergo bilateral orchiectomy or LHRH agonist therapy
           comprising goserelin subcutaneously (SC) every 4 weeks (short-acting formulation) or
           every 3 months (long-acting formulation), leuprolide intramuscularly every 4 weeks
           (short-acting formulation) or every 3 months (long-acting formulation), or buserelin SC
           every 8 weeks or every 12 weeks. Patients choosing orchiectomy may receive an
           antiandrogen for at least 6 weeks before surgery to counter any flare phenomenon and may
           continue the antiandrogen after surgery (at the physician's discretion).

        -  Arm II: Patients undergo total androgen ablation as in arm I. Patients with
           node-negative dissection undergo radiotherapy 5 days a week for 6.5-7 weeks. All other
           patients undergo radiotherapy 5 days a week for 5 weeks, followed by boost radiotherapy
           5 days a week for 2-2.4 weeks.

      Hormonal therapy on both arms continues in the absence of disease progression or unacceptable
      toxicity.

      Quality of life is assessed at baseline, on the last day of radiotherapy, at 6 months, and
      then every 6 months thereafter.

      Patients are followed at 1, 2, and 6 months and then every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 1,200 patients will be accrued for this study within 7.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1995</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic local control measured by surgical intervention rate</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC-QLQ-C30 + 3 and a trial-specific checklist (PR17) or the FACT-P questionnaire</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">361</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <description>Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk</description>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buserelin</intervention_name>
    <description>Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk</description>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flutamide</intervention_name>
    <description>Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk</description>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin</intervention_name>
    <description>Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk</description>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leuprolide acetate</intervention_name>
    <description>Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk</description>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilutamide</intervention_name>
    <description>Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk</description>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>orchiectomy</intervention_name>
    <description>Optional orchiectomy</description>
    <arm_group_label>Total Androgen Blockade</arm_group_label>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)</description>
    <arm_group_label>Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven locally advanced adenocarcinoma of the prostate, defined as 1 of
             the following:

               -  T3-4, N0 or NX, M0

               -  T2, PSA greater than 40 µg/L

               -  T2, PSA greater than 20 µg/L AND Gleason score at least 8

          -  Diagnosis made within the past 6 months

          -  Gleason score and PSA known

          -  Pelvic lymph nodes must be clinically negative

               -  Lymph nodes no more than 1.5 cm in greatest diameter by CT scan or MRI of the
                  pelvis

               -  Negative needle aspirate required for any lymph node more than 1.5 cm

               -  If a lymph node dissection was performed, it must be histologically negative

          -  No small cell or transitional cell carcinoma by biopsy

          -  No bony metastases by bone scan

        PATIENT CHARACTERISTICS:

        Age:

          -  Under 80

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  At least 5 years excluding malignancy

        Hematopoietic:

          -  Hemoglobin at least 10.0 g/dL

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 2 times upper limit of normal (ULN)

          -  SGOT and SGPT less than 2 times ULN

          -  Alkaline phosphatase less than 2 times ULN

          -  No history of chronic liver disease

        Renal:

          -  Creatinine less than 2 times ULN

        Other:

          -  No contraindication to wide-field pelvic irradiation (e.g., inflammatory bowel disease
             or severe bladder irritability)

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Prior hormonal therapy within the past 12 weeks allowed provided the following
             conditions are met:

               -  Negative bone scan before beginning any hormonal therapy

               -  Extracapsular extension remains palpable on rectal re-exam

               -  Baseline PSA known before beginning any hormonal therapy

          -  At least 4-6 weeks since prior 5-alpha-reductase inhibitor (e.g., finasteride) for
             benign prostatic hypertrophy

        Radiotherapy:

          -  No prior pelvic irradiation

        Surgery:

          -  No prior radical prostatectomy

          -  Prior transurethral resection of the prostate allowed

        Other:

          -  No prior cytotoxic anticancer therapy

          -  No other prior treatment for prostate cancer

          -  No other concurrent anticancer therapy unless documented disease progression
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Padraig R. Warde, MB, MRCPI, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard R. Whittington, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Srinivasan Vijayakumar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Michael Reese Hospital and Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Lillis-Hearne, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcolm D. Mason, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Velindre NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Fraser Valley Cancer Centre</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre at Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Health Research Institute - General Division</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Program of the Hopital Regional</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunder Bay Regional Health Science Centre</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Health Network-Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Dept. Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A, Parmar MK, Sathya J, Anderson J, Hayter C, Hetherington J, Sydes MR, Parulekar W; NCIC CTG PR.3/MRC UK PR07 investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011 Dec 17;378(9809):2104-11. doi: 10.1016/S0140-6736(11)61095-7. Epub 2011 Nov 2.</citation>
    <PMID>22056152</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 31, 2014</last_update_submitted>
  <last_update_submitted_qc>January 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Buserelin</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Flutamide</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Nilutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

